Modeling Endpoints: How to Model Anti-Drug Antibody Data in Nonclinical Studies

From PHUSE Wiki
Revision as of 09:43, 14 June 2017 by Mwasko79 (talk | contribs) (Conference Calls and Minutes)
Jump to: navigation, search

Welcome to the site for the "Investigating Endpoint Modeling - How to Model Anti-Drug Antibody Data in Nonclinical Studies" project group.

This page describes high-level project management details on the group, including purpose, milestones, attendees, and so on. We are part of the FDA/PhUSE Computational Sciences Nonclinical Working Group. Learn more about the larger working group at Non-Clinical Road-map and Impacts on Implementation.

Working Group Overview

Identified Need/Challenge

Project Scope





  • Determine endpoints
  • Call for Participants
  • Maintain wiki (ongoing)
  • Research CDISC ADA


Participation Needs

Call for participation!

What is the commitment?

  • Time (minimum of 1 hour every two weeks for team meetings, up to 3 hours / month)
  • Expected to contribute, not just be a spectator
  • Contribution of viewpoints and content
  • Wiki - creating/reviewing page content

If you would like to participate, please contact the co-leads for this group: Mike Wasko ( and Debra Oetzman (

Work Group Participants


  • Mike Wasko, PDS
  • Gretchen Dean, Pfizer
  • Thomas Gade Bjerregaard


Conference Calls and Minutes

Investigating Endpoint Modeling - ADA Minutes

Last revision by Mwasko79, 2017-06-14